Skip to content

Study · Observational study · n = 78 · 2026

9 results

Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study.

Gilardini L, Vincenti V, Croci M, Martinelli S, Pasqualinotto L, Toja P, Cavaggioni L, Bertoli S

Journal of obesity1 Jan 2026Cited by 1 (Europe PMC)

PMID42658045 (opens in a new tab)PMCIDPMC13520785 (opens in a new tab)DOI10.1155/jobe/1224246 (opens in a new tab)PepBankPUB-42658045
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

ObjectiveThis prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.MethodsThe weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)). Before and after the intervention, anthropometry, body composition, blood pressure, level of physical activity, nutrition knowledge, quality of life, and daytime sleepiness were assessed.ResultsOf 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost. Liraglutide was well tolerated. Four subjects complained of nausea and two of epigastralgia. During the 6-12-week period, the weight loss was -3.5 ± 1.8 kg (-3.2%) in the eUR-LT group and -1.3 ± 1.6 kg (-1.4%) in the eUR-NLT, p < 0.001. Using liraglutide therapy, baseline body mass index, sex, age, and weight change at 6 weeks as independent variables, the multivariate regression analysis found that only liraglutide therapy was significantly associated with weight loss from Week 6 to Week 12 (p < 0.001). After 12 weeks, total weight loss was -6.0 ± 2.4 kg (-5.3%) in group eUR-LT, -2.4 ± 1.9 kg (-2.4%) in group eUR-NLT, and -6.2 ± 2.3 kg (-6.3%) in group eR. In the eUR-LT group, 66.7% lost ≥ 5% of the initial weight; in group eUR-NLT, 14%; and in group eR, 72.9%.ConclusionLiraglutide therapy is beneficial for individuals with obesity who do not respond early to lifestyle intervention. However, the high cost of the drug remains a barrier to its use.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In early lifestyle nonresponders with obesity, weeks 6-12 weight change was-3.5±1.8 kg(-3.2%) with liraglutide versus-1.3±1.6 kg(-1.4%) among decliners (P < 0.001;±measure unspecified).

    In plain wordsIn early lifestyle nonresponders with obesity, liraglutide use was linked to greater weight reduction than declining treatment during weeks 6-12.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss from week 6 to week 12
    Study

    n = 78

    Comparator
    Early unresponders declining liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change
    −3.5 kg
    liraglutide;weeks 6-12;reported±1.8,P < .001
    Weight change
    −1.3 kg
    decliners;weeks 6-12;reported±1.6,P < .001
    Weight change
    −3.2%
    liraglutide;weeks 6-12
    Weight change
    −1.4%
    decliners;weeks 6-12

    Source sentences

    Summary
    During the 6-12-week period, the weight loss was -3.5 ± 1.8 kg (-3.2%) in the eUR-LT group and -1.3 ± 1.6 kg (-1.4%) in the eUR-NLT, p < 0.001.
    3 context sentences
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  2. 02HumanObservational studyEfficacy outcome

    In early lifestyle nonresponders with obesity, week 12 weight change was-6.0±2.4 kg(-5.3%) with liraglutide versus-2.4±1.9 kg(-2.4%) among decliners (±measure unspecified).

    In plain wordsIn early lifestyle nonresponders with obesity, liraglutide use was linked to greater total weight reduction than declining treatment by study week 12.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal weight loss after 12 weeks
    Study

    n = 78

    Comparator
    Early unresponders declining liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change
    −6 kg
    liraglutide;study week 12;reported±2.4
    Weight change
    −2.4 kg
    decliners;study week 12;reported±1.9
    Weight change
    −5.3%
    liraglutide;study week 12
    Weight change
    −2.4%
    decliners;study week 12

    Source sentences

    Summary
    After 12 weeks, total weight loss was -6.0 ± 2.4 kg (-5.3%) in group eUR-LT, -2.4 ± 1.9 kg (-2.4%) in group eUR-NLT, and -6.2 ± 2.3 kg (-6.3%) in group eR.
    3 context sentences
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  3. 03HumanObservational studyEfficacy outcome

    At study week 12, 66.7% of liraglutide users and 14% of early lifestyle nonresponders with obesity who declined treatment achieved at least 5% weight loss.

    In plain wordsIn early lifestyle nonresponders with obesity, more liraglutide users than decliners achieved at least 5% weight reduction by study week 12.

    Peptide
    Liraglutide
    Outcome
    IncreaseLoss of at least 5% initial weight
    Study

    n = 78

    Comparator
    Early unresponders declining liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    At least5%weight-loss responders
    66.7%
    liraglutide;study week 12
    At least5%weight-loss responders
    14%
    decliners;study week 12

    Source sentences

    Summary
    In the eUR-LT group, 66.7% lost ≥ 5% of the initial weight; in group eUR-NLT, 14%; and in group eR, 72.9%.
    3 context sentences
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  4. 04HumanObservational studySafety outcome

    Liraglutide was well tolerated in early lifestyle non-responders with obesity.

    In plain wordsIn early lifestyle nonresponders with obesity, liraglutide was well tolerated.

    Peptide
    Liraglutide
    Outcome
    Not applicableOverall tolerability
    Study

    n = 21

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide was well tolerated.
    3 context sentences
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  5. 05HumanObservational studySafety outcome

    In 21 early lifestyle nonresponders with obesity receiving liraglutide, four reported nausea.

    In plain wordsIn 21 early lifestyle nonresponders with obesity receiving liraglutide, four reported nausea.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea
    Study

    n = 21

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Four subjects complained of nausea and two of epigastralgia.
    4 context sentences
    Summary · context
    Liraglutide was well tolerated.
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  6. 06HumanObservational studySafety outcome

    In 21 early lifestyle nonresponders with obesity receiving liraglutide, two reported epigastralgia.

    In plain wordsIn 21 early lifestyle nonresponders with obesity receiving liraglutide, two reported upper-abdominal pain.

    Peptide
    Liraglutide
    Outcome
    Not applicableEpigastralgia
    Study

    n = 21

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Four subjects complained of nausea and two of epigastralgia.
    4 context sentences
    Summary · context
    Liraglutide was well tolerated.
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  7. 07HumanObservational studyOther

    In lifestyle-program participants with obesity, liraglutide therapy was the only regression covariate significantly associated with weeks 6-12 weight loss (P < 0.001); association sign and analysis N were unstated.

    In plain wordsIn lifestyle-program participants with obesity, liraglutide therapy was linked to weeks 6-12 weight loss in regression; the association sign was unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedAssociation with weight loss from week 6 to week 12
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using liraglutide therapy, baseline body mass index, sex, age, and weight change at 6 weeks as independent variables, the multivariate regression analysis found that only liraglutide therapy was significantly associated with weight loss from Week 6 to Week 12 (p < 0.001).
    3 context sentences
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  8. 08HumanObservational studyEfficacy outcome

    In participants with obesity at study week 12, liraglutide users had smaller reported weight-reduction magnitude than early lifestyle responders (changes-6.0±2.4 kg[-5.3%] versus-6.2±2.3 kg[-6.3%];±measure unspecified).

    In plain wordsIn participants with obesity, liraglutide users had smaller reported weight-reduction magnitude than early lifestyle responders at study week 12.

    Peptide
    Liraglutide
    Outcome
    DecreaseMagnitude of weight reduction versus early lifestyle responders
    Study

    n: not reported in source

    Comparator
    Early lifestyle responders
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change
    −6 kg
    liraglutide;study week 12;reported±2.4
    Weight change
    −6.2 kg
    early lifestyle responders;study week 12;reported±2.3
    Weight change
    −5.3%
    liraglutide;study week 12
    Weight change
    −6.3%
    early lifestyle responders;study week 12

    Source sentences

    Summary
    After 12 weeks, total weight loss was -6.0 ± 2.4 kg (-5.3%) in group eUR-LT, -2.4 ± 1.9 kg (-2.4%) in group eUR-NLT, and -6.2 ± 2.3 kg (-6.3%) in group eR.
    3 context sentences
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.
  9. 09HumanObservational studyEfficacy outcome

    At study week 12, 66.7% of liraglutide users and 72.9% of early lifestyle responders with obesity achieved at least 5% weight loss.

    In plain wordsIn participants with obesity, fewer liraglutide users than early lifestyle responders achieved at least 5% weight loss by study week 12.

    Peptide
    Liraglutide
    Outcome
    DecreaseAt least 5% weight-loss responders at study week 12
    Study

    n: not reported in source

    Comparator
    Early lifestyle responders
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    At least5%weight-loss responders
    66.7%
    liraglutide;study week 12
    At least5%weight-loss responders
    72.9%
    early lifestyle responders;study week 12

    Source sentences

    Summary
    In the eUR-LT group, 66.7% lost ≥ 5% of the initial weight; in group eUR-NLT, 14%; and in group eR, 72.9%.
    3 context sentences
    Summary · context
    This prospective, observational study examined the efficacy of liraglutide in subjects with obesity who did not experience early weight loss during a behavioral intervention in a real-world setting.
    Summary · context
    The weight loss intervention lasted for 12 weeks, and at Week 6, we offered liraglutide to subjects who had lost less than 2.5% of their body weight (early unresponder (eUR)).
    Summary · context
    Of 174 participants, 78 subjects were classified as early unresponders: 21 (27%) agreed to start liraglutide therapy (eUR-LT), and 57 declined (eUR-NLT), primarily due to the out-of-pocket cost.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.